

Hypoplasia in PNH : to treat or not to treat?

Andrea Bacigalupo and Hubert Schrezenmeier

Rome

Ulm

Firenze 4/October/2024

Disclosures

Speakers Bureau for

Sanofi, Pfizer, Therakos, Adienne, MSD, Novartis, Riemsler, Eurocept, Takeda, Pierre Fabre, Miltenyi, Jazz

Advisory Board for

Novartis, Jazz, Kiadis, MSD, Clinigen

Hypoplasia in PNH

PNH and AA

AA and PNH

AA/ PNH

MDS/PNH

60 year old lady

Diagnosis of RA in 2016 (with cytopenia ; mainly platelets)

Enrolled in a trial of EPAG in low risk MDS

No response of cytopenia

Activated UD search (2020) – identified MUD 8/8

Patient admitted for transplant-

High LDH prompts search for GPI- cells

Large PNH clone identified







Patient discharged and started on eculizumab


2024 patient AW on eculizumab

PNH misdiagnosed as MDS

How many patients with AA have PNH clones?

A longitudinal analysis of paroxysmal nocturnal haemoglobinuria-type cells in patients with bone marrow failure: Results of a prospective multi-centre study in Japan

Ken Ishiyama^{1,2,3}  | Yuji Yonemura^{3,4} | Tatsuya Kawaguchi^{3,5} | Kohei Hosokawa^{1,3}  |
 Chiharu Sugimori^{3,6} | Yasutaka Ueda^{3,7} | Hiroyuki Takamori^{3,7} | Naoshi Obara^{3,8}  |
 Hideyoshi Noji^{3,9} | Yukari Shirasugi^{3,10} | Kiyoshi Ando^{3,10} | Tsutomu Shichishima^{3,9} |
 Haruhiko Ninomiya^{3,11} | Shigeru Chiba^{3,11}  | Jun-ichi Nishimura^{3,7}  |
 Yuzuru Kanakura^{3,7} | Shinii Nakao^{1,3} 



1075

900

144

283

PNH+ PMN 52%

13%

100%

3%



Myelodysplastic syndrome

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia

3085 patients
869 MDS
531 AA

Bruno Fattizzo ^{1,2,3} · Robin Ireland¹ · Alan Dunlop¹ · Deborah Yallop¹ · Shireen Kassam¹ · Joanna Large¹ · Shreyans Gandhi¹ · Petra Muus¹ · Charles Manogaran¹ · Katy Sanchez¹ · Dario Consonni² · Wilma Barcellini² · Ghulam J. Mufti^{1,4} · Judith C. W. Marsh^{1,4} · Austin G. Kulasekararaj ^{1,4}

AA 61% PNH+
MDS 20% PNH+

Other malign 9-12%

How many patients with AA have PNH clones: 52%- 61%

what % of PNH clones are circulating ?

A longitudinal analysis of paroxysmal nocturnal haemoglobinuria-type cells in patients with bone marrow failure: Results of a prospective multi-centre study in Japan



At the start of follow-up

Gr. A: PNH-type granulocytes 0.003 - 0.1%

Gr. B: PNH-type granulocytes 0.1 - 1%

Gr. C: PNH-type granulocytes $\geq 1\%$

End of follow-up



1075	900	144	283
↓ 52%	13%	100%	3%

25% 0.003-0.1%

25% 0.1-1%

50% $\geq 1\%$

How many patients with AA have PNH clones: 52%- 61%

what % of PNH clones are circulating : 50% have $\geq 1\%$

what is AA/PNH ?

AA/PNH definition

any patient with a diagnosis of AA and a PNH clone

independent of the size of the PNH clone

independent of peripheral blood counts

independent of LDH levels

independent of transfusion requirement

independent of thrombosis

How many patients with AA have PNH clones: 52%- 61%

what % of PNH clones are circulating : 50% have $\geq 1\%$

hypoplastic PNH : any AA with a PNH clone

do we treat hypoplastic PNH ?

AA/PNH

hematology

PNH clone

LDH

treat

A *cytopenia TD* *yes*

low

AA

B *cytopenia Ti* *yes*

low

AA??

65 year old ; PMN 800; Plt 40; Hb 10 LDH 180
gran 2% Mono 3%, RBC 0.5% → options

W & W

CSA

EPAG

ATG

thrombosis prophylaxis YES NO

45 year old ; PMN 800; Plt 40; Hb 10
gran 20% Mono 3%, RBC 25% **LDH 1000** → options

eculizumab alone

eculizumab + CSA +/- EPAG

eculizumab + ATG

W&W

thrombosis prophylaxis YES NO

AA/PNH

	<i>hematology</i>	<i>PNH clone</i>	<i>LDH</i>	<i>treat</i>
<i>A</i>	<i>cytopenia TD</i>	<i>yes</i>	<i>low</i>	<i>AA</i>
<i>B</i>	<i>cytopenia Ti</i>	<i>yes</i>	<i>low</i>	<i>AA</i>
<i>C</i>	<i>PR /CR</i>	<i>yes</i>	<i>low</i>	<i>AA</i>
<i>D</i>	<i>PR /CR</i>	<i>yes</i>	<i>HIGH</i>	<i>PNH</i>

In AA/PNH

How high should the LDH be to use eculizumab (AA/PNH)

X2 normal value

X3 normal value

AA/PNH

	<i>hematology</i>	<i>PNH clone</i>	<i>LDH</i>	<i>treat</i>
<i>A</i>	<i>cytopenia TD</i>	<i>yes</i>	<i>low</i>	<i>AA</i>
<i>C</i>	<i>cytopenia Ti</i>	<i>yes</i>	<i>low</i>	<i>AA</i>
<i>D</i>	<i>PR /CR</i>	<i>yes</i>	<i>low</i>	<i>AA</i>
<i>E</i>	<i>PR /CR</i>	<i>yes</i>	<i>HIGH</i>	<i>PNH</i>

How high?

expert consensus in Japan : 3 fold normal value


(Shinji Nakao)

52 year old lady with cytopenia

SAA

PNH MDS

AML



**ATG
+CsA**

PR-> CR

**Splenomegaly
Portal Thromb
LDH++
No Transfus**

Platelets

GPI- cells

+ 8


Patient 1

would have been eligible for anti-C treatment

not available in 1994

??would not have prevented MDS-AML (+8 present in G-SCF mobilized PB cells collected at diagnosis)

25 year old pt with cytopenia



Treatment of AA/PNH

Depends on

degree of cytopenia (AA)

level of PNH clone and LDH (PNH)

- SAA WP
- Regis Peffault de la Toutr and Antonio Risitano
- Carlo Dufour, Ajstin Kulasekararaji, Anna Locasciulli, Franco Locatelli, Christina Peters, Rosi Oneto, Jacob Passweg,
- Maria Teresa Van Lint, Gérard Socié, Andre Tichelli , Judith Marsh; Hubert Schrezenmeier, Carlos Vallejo

- N Young, P Scheinberg, J Deeg, S Nakao , S Kojima ,
- Xiaofan Zhu, Xiaojuan Chen, Surapol Issaragrisil, Suporn Chuncharunee , Dae Chul Jeong , Yizhou Zheng



50% of Aplastic Anemia patients have a PNH clone; these GPI- cells may be spared by the immune attack

*GPI- cells should be monitored with time :
increased **GPI- cells** and/or **LDH** and/or
spleen and/or **thrombosis** should alert
on the evolution towards PNH*


Patient 1

would have been eligible for anti-C treatment

not available in 1994

would not have prevented MDS-AML (+8 present in G-SCF mobilized PB cells collected at diagnosis)

**52 year old lady
with
cytopenia**



Patient 2

AA in CR after ATG CSA


PNH clone stable over years / normal LDH

granulocytes 2%


monocytes 1.4%

erythrocytes 0.2%


25 year old pt with cy




25 year old pt with cytopenia



25 year old pt with cytopenia



25 year old pt with cytopenia



Patient 3

AA in CR after ATG

AA/ PNH developed after 6 years- untreated

**# the PNH clone underwent spontaneous reduction
over several years**

ARTICLE



Myelodysplastic syndrome

Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia

3085 patients
869 MDS
531 AA

Bruno Fattizzo^{1,2,3} · Robin Ireland¹ · Alan Dunlo Shreyans Gandhi¹ · Petra Muus¹ · Charles Manoga Ghulam J. Mufti^{1,4} · Judith C. W. Marsh^{1,4} · Austin

AA 61% PNH+
MDS 20% PNH+

Other malign 9-12%

PNH clone size on PMN according to diagnosis

- AA
- MDS
- ISOLATED THROMBOSIS
- ISOLATED CYTOPENIA
- OTHERS
- ISOLATED PNH

